Black Diamond Therapeutics, Inc. (BDTX) stock
BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.44−0.09 (-5.88%)
Close on Nov 17, 2026Market cap $82.73MP/E –Yield –
Black Diamond Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Black Diamond Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$51.90M, down 1203.2% year over year. For fiscal 2025 it was $12.52M. The highest annual figure on record is $12.52M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.52M | – |
| FY2024 | Dec 31, 2024 | -$78.78M | – |
| FY2023 | Dec 31, 2023 | -$86.46M | – |
| FY2022 | Dec 31, 2022 | -$92.83M | – |
| FY2021 | Dec 31, 2021 | -$126.87M | – |
| FY2020 | Dec 31, 2020 | -$69.57M | – |
| FY2019 | Dec 31, 2019 | -$29.33M | – |
| FY2018 | Dec 31, 2018 | -$8.90M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.06M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.26M | -120.6% |
| Q4 FY2025 | Dec 31, 2025 | -$17.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.98M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.42M | – |
| Q1 FY2025 | Mar 31, 2025 | $54.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$22.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.01M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.03M | – |
| Q1 FY2023 | Mar 31, 2023 | -$21.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.12M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.17M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.68M | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$35.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$34.72M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.71M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.18M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.48M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.03M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.34M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.15M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.00M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.84M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.05M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.34M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.91M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.61M | – |
See a number that looks wrong?